Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international subscription-based journal publishing review articles and original papers on novel molecular targets, providing expert opinion on the scope for future drug development and the impact on drug discovery.
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.
The Editors welcome:
- Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
- Articles should not include clinical information including specific drugs and clinical trials.
- Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Therapeutic Targets, part of the Expert Collection brand.
Authors can choose to publish gold open access in this journal.
Read the Instructions for Authors for information on how to submit your article.
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110803/Subject-Sample-2021-Bioscience.jpg"})